Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

Trial: NivoRd, single-arm phase II (NCT02903381; Dana-Farber IRB 16-242). n = 8 patients with high-risk smoldering multiple myeloma treated with nivolumab + lenalidomide + dexamethasone. Patients identified by opaque codes (Pt01, Pt03-Pt09).
Contents: per-cell imaging mass cytometry (IMC) AnnData; scRNA-seq AnnData for CD138-negative immune and CD138-positive plasma cells (NivoRd cells only); IMC phenotype tables (canonical 7-class lineages, Leiden clusters, 8 cellular neighborhoods); per-sample IMC summaries; LIANA differential ligand-receptor interactions; cytogenetic-vs-expression validation tables; MSigDB Hallmark 2020 GMT; per-patient response classifiers (DOR, COT, FAST, DOR_ordinal); README + data dictionary.
License: CC BY 4.0. Code: https://github.com/ghobriallab/NivoRd_trial_2026
v3 changelog: response group labels relabeled per IMWG conventions — "R" → "DR" (deep responders; CR/VGPR) and "NR" → "P-NR" (partial / non-responders; PR/SD). Updated files: README.md, DATA_DICTIONARY.md, patient_response_groups.csv. All other files unchanged.